Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors

Next Previous
Trial Profile

A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MEN 1309 (Primary) ; Balstilimab; Pembrolizumab
  • Indications Adenoid cystic carcinoma; Bladder cancer; Gastric cancer; Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Oxford BioTherapeutics

Most Recent Events

  • 30 Apr 2025 Results assessing Preliminary activity and safety of OBT076 in patients with CD205 positive solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research
  • 30 Apr 2025 Results assessing Preliminary activity and safety of OBT076 in patients with CD205 positive solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research
  • 24 Nov 2023 Planned number of patients changed from 150 to 200.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top